Effects of ADP and epinephrine on PGE1 (1 µM)–induced increase of cAMP levels in platelets from patient III-7 and healthy controls
| . | cAMP (% of PGE1-induced) . | ||
|---|---|---|---|
| Patient III-7, experiment 1 . | Patient III-7, experiment 2 . | Healthy controls* (n = 21) . | |
| ADP (0.1 μM) | 90.0 | 92.8 | 78.62 ± 11.58 |
| ADP (1.0 μM) | 107.0 | 100.0 | 44.41 ± 11.88 |
| Epinephrine (1 μM) | 22.0 | 26.0 | 30.36 ± 13.94 |
| . | cAMP (% of PGE1-induced) . | ||
|---|---|---|---|
| Patient III-7, experiment 1 . | Patient III-7, experiment 2 . | Healthy controls* (n = 21) . | |
| ADP (0.1 μM) | 90.0 | 92.8 | 78.62 ± 11.58 |
| ADP (1.0 μM) | 107.0 | 100.0 | 44.41 ± 11.88 |
| Epinephrine (1 μM) | 22.0 | 26.0 | 30.36 ± 13.94 |
PRP containing trisodium citrate as anticoagulant was exposed to PGE1 (1 μM) in the presence or absence of ADP or epinephrine at the indicated concentrations for 2 minutes at 37°C (see “Methods” for details).
Means ± SD.